Table 2.
Calcium mobilization studies
| NOP | MOP | DOP | KOP | |
|---|---|---|---|---|
| pEC50 (CL95%) | pEC50 (CL95%) | pEC50 (CL95%) | pEC50 (CL95%) | |
| N/OFQ | 9.39 (9.23–9.57) | <6 | <6 | <6 |
| PWT1-N/OFQ | 8.75 (8.35–9.15) | <6 | <6 | <6 |
| PWT2-N/OFQ | 8.83 (8.47–9.18) | <6 | <6 | <6 |
| PWT3-N/OFQ | 9.16 (9.08–9.24) | <6 | <6 | <6 |
| Dermorphin | <6 | 9.29 (9.19–9.38) | <6 | <6 |
| DPDPE | <6 | <6 | 9.57 (9.03–10.11) | <6 |
| Dynorphin A | <6 | 6.76 (6.50–7.02) | 7.63 (7.38–7.88) | 10.04 (9.93–10.16) |
Potencies of N/OFQ, its PWT derivatives and standard opioid agonists in CHO cells expressing the human NOP or classical opioid receptors and chimeric G proteins. Data are the mean of three separate experiments performed in duplicate.